{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T04:21:46Z","timestamp":1787458906845,"version":"build-2736575974"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.tice.2026.103747","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:22:10Z","timestamp":1782850930000},"page":"103747","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Dapagliflozin uncouples the anti-inflammatory and lipogenic effects of pioglitazone in valproic acid-induced steatohepatitis in rats: Lipid-sensing nuclear receptors (LXR\u03b1 and PPAR\u03b3) as the molecular nexus between hepatoprotection and lipogenesis"],"prefix":"10.1016","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5242-3713","authenticated-orcid":false,"given":"Rania G.","family":"Elkatary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha O.","family":"Hammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hend M.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaya","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina S.","family":"Elshenawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.tice.2026.103747_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s40268-014-0042-z","article-title":"Valproate-Induced Liver Injury: Modulation by the Omega-3 Fatty Acid DHA Proposes a Novel Anticonvulsant Regimen","volume":"14","author":"Abdel-Dayem","year":"2014","journal-title":"Drugs R. &D."},{"issue":"17\u201318","key":"10.1016\/j.tice.2026.103747_bib2","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.drudis.2007.07.009","article-title":"Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD)","volume":"12","author":"Ahmed","year":"2007","journal-title":"Drug. Discov. Today"},{"issue":"4","key":"10.1016\/j.tice.2026.103747_bib3","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2008.06.047","article-title":"Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects with Nonalcoholic Steatohepatitis","volume":"135","author":"Aithal","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.tice.2026.103747_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122182","article-title":"The implication of LPS\/TLR4 and FXR receptors in hepatoprotective efficacy of indole-3-acetic acid and chenodeoxycholic acid","volume":"334","author":"Aljarboa","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.tice.2026.103747_bib5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.taap.2017.03.022","article-title":"Valproate induced hepatic steatosis by enhanced fatty acid uptake and triglyceride synthesis","volume":"324","author":"Bai","year":"2017","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"7","key":"10.1016\/j.tice.2026.103747_bib6","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2337\/db09-0797","article-title":"Gamma-aminobutyric acid (GABA) is an autocrine excitatory transmitter in human pancreatic beta-cells","volume":"59","author":"Braun","year":"2010","journal-title":"Diabetes"},{"key":"10.1016\/j.tice.2026.103747_bib7","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.tox.2017.11.013","article-title":"Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction","volume":"393","author":"van Breda","year":"2018","journal-title":"Toxicology"},{"issue":"7","key":"10.1016\/j.tice.2026.103747_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11072071","article-title":"Dietary Supplementation with 20-Hydroxyecdysone Ameliorates Hepatic Steatosis and Reduces White Adipose Tissue Mass in Ovariectomized Rats Fed a High-Fat, High-Fructose Diet","volume":"11","author":"Buniam","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.tice.2026.103747_bib9","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9576503","article-title":"Study of valproic acid-enhanced hepatocyte steatosis","volume":"2016","author":"Chang","year":"2016","journal-title":"BioMed. Res. Int."},{"issue":"5","key":"10.1016\/j.tice.2026.103747_bib10","first-page":"241","article-title":"Double staining immunohistochemistry","volume":"2","author":"Chen","year":"2010","journal-title":"North. Am. J. Med. Sci."},{"issue":"6","key":"10.1016\/j.tice.2026.103747_bib11","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1007\/s10753-010-9281-5","article-title":"Elevated expression of liver X receptor alpha (LXR\u03b1) in myocardium of streptozotocin-induced diabetic rats","volume":"34","author":"Cheng","year":"2011","journal-title":"Inflammation"},{"issue":"9","key":"10.1016\/j.tice.2026.103747_bib12","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.clinthera.2024.06.023","article-title":"Efficacy and Safety of Pioglitazone Add-on in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin and Dapagliflozin: A Multicenter, Randomized, Double-blind, and Placebo-controlled Study","volume":"46","author":"Cho","year":"2024","journal-title":"Clin. Ther."},{"issue":"7","key":"10.1016\/j.tice.2026.103747_bib13","doi-asserted-by":"crossref","first-page":"G526","DOI":"10.1152\/ajpgi.00243.2015","article-title":"Pioglitazone attenuates hepatic inflammation and fibrosis in phosphatidylethanolamine N-methyltransferase-deficient mice","volume":"310","author":"van der Veen","year":"2016","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.tice.2026.103747_bib14","first-page":"187","article-title":"Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes","volume":"32","author":"Dormandy","year":"2013","journal-title":"Drug. Saf. 2009 32"},{"issue":"1","key":"10.1016\/j.tice.2026.103747_bib15","doi-asserted-by":"crossref","DOI":"10.1080\/21623945.2023.2179334","article-title":"An optimized method for Oil Red O staining with the salicylic acid ethanol solution","volume":"12","author":"Du","year":"2023","journal-title":"Adipocyte"},{"issue":"19","key":"10.1016\/j.tice.2026.103747_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38081","article-title":"Melatonin mitigates doxorubicin induced chemo brain in a rat model in a NRF2\/p53-SIRT1 dependent pathway","volume":"10","author":"Ebrahim","year":"2024","journal-title":"Heliyon"},{"issue":"7\u20138","key":"10.1016\/j.tice.2026.103747_bib17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.bbalip.2011.04.014","article-title":"Eicosapentaenoic acid ablates valproate-induced liver oxidative stress and cellular derangement without altering its clearance rate: Dynamic synergy and therapeutic utility","volume":"1811","author":"El-Mowafy","year":"2011","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Cell Biology Lipids"},{"issue":"9","key":"10.1016\/j.tice.2026.103747_bib18","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1369\/00221554211041607","article-title":"Independent of Calorie Intake, Short-term Alternate-day Fasting Alleviates NASH, With Modulation of Markers of Lipogenesis, Autophagy, Apoptosis, and Inflammation in Rats","volume":"69","author":"Elsayed","year":"2021","journal-title":"J. Histochem. Cytochem."},{"issue":"162","key":"10.1016\/j.tice.2026.103747_bib19","article-title":"Valproic acid induced liver injury: An insight into molecular toxicological mechanism","volume":"95","author":"Ezhilarasan","year":"2022","journal-title":"Environ. Toxicol. Pharmacol."},{"issue":"4","key":"10.1016\/j.tice.2026.103747_bib20","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1208\/s12248-016-9919-9","article-title":"Dual Outcomes of Rosiglitazone Treatment on Fatty Liver","volume":"18","author":"Gao","year":"2016","journal-title":"AAPS J."},{"issue":"2","key":"10.1016\/j.tice.2026.103747_bib21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/br.2024.1904","article-title":"Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes","volume":"22","author":"Gao","year":"2025","journal-title":"Biomed. Rep."},{"issue":"6","key":"10.1016\/j.tice.2026.103747_bib22","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1185\/030079903125002180","article-title":"Effects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitus","volume":"19","author":"Gerber","year":"2003","journal-title":"Curr. Med. Res. Opin."},{"issue":"3","key":"10.1016\/j.tice.2026.103747_bib23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/1381612825666190329145428","article-title":"Valproic Acid and the Liver Injury in Patients with Epilepsy: An Update","volume":"25","author":"Guo","year":"2019","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.tice.2026.103747_bib24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ebiom.2017.12.021","article-title":"Synthetic High-Density Lipoprotein-Mediated Targeted Delivery of Liver X Receptors Agonist Promotes Atherosclerosis Regression","volume":"28","author":"Guo","year":"2018","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.tice.2026.103747_bib25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bcp.16233","article-title":"L-carnitine for valproic acid-induced toxicity","volume":"91","author":"Gziut","year":"2025","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.tice.2026.103747_bib26","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.procbio.2023.04.029","article-title":"Simplified protocol modification of TRIzol method for extraction of high-quality RNA yield from RNase-rich rat pancreas","volume":"130","author":"Hammad","year":"2023","journal-title":"Process. Biochem."},{"issue":"11","key":"10.1016\/j.tice.2026.103747_bib27","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.7150\/thno.108593","article-title":"Mechanism of valproic acid-induced hepatic steatosis via enhancing NRF2-FATP2-mediated fatty acid uptake","volume":"15","author":"He","year":"2025","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.tice.2026.103747_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10051032","article-title":"Empagliflozin Reduces the Progression of Hepatic Fibrosis in a Mouse Model and Inhibits the Activation of Hepatic Stellate Cells via the Hippo Signalling Pathway","volume":"10","author":"Heo","year":"2022","journal-title":"Biomedicines"},{"issue":"11","key":"10.1016\/j.tice.2026.103747_bib29","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/j.1872-034X.2008.00382.x","article-title":"Liver X receptor in cooperation with SREBP-1c is a major lipid synthesis regulator in nonalcoholic fatty liver disease","volume":"38","author":"Higuchi","year":"2008","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.tice.2026.103747_bib30","doi-asserted-by":"crossref","first-page":"12213","DOI":"10.3390\/ijms160612213","article-title":"Effect of Chronic Pioglitazone Treatment on Hepatic Gene Expression Profile in Obese C57BL\/6J Mice","volume":"16","author":"Jia","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tice.2026.103747_bib31","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.fct.2014.08.009","article-title":"Role of Nrf2 activation and NF-\u03baB inhibition in valproic acid induced hepatotoxicity and in diammonium glycyrrhizinate induced protection in mice","volume":"73","author":"Jin","year":"2014","journal-title":"Food Chem. Toxicol."},{"key":"10.1016\/j.tice.2026.103747_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116167","article-title":"Dapagliflozin ameliorates hepatic steatosis via suppressing LXR\u03b1-mediated synthesis of lipids and bile acids","volume":"223","author":"Jin","year":"2024","journal-title":"Biochem. Pharmacol."},{"issue":"1","key":"10.1016\/j.tice.2026.103747_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2004.01.038","article-title":"Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet","volume":"315","author":"Kawaguchi","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"8","key":"10.1016\/j.tice.2026.103747_bib34","doi-asserted-by":"crossref","first-page":"503","DOI":"10.3949\/ccjm.92a.24071","article-title":"Managing the side effects of sodium-glucose cotransporter-2 inhibitors","volume":"92","author":"Kodur","year":"2025","journal-title":"Clevel. Clin. J. Med."},{"issue":"3","key":"10.1016\/j.tice.2026.103747_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0151511","article-title":"Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction","volume":"11","author":"Komiya","year":"2016","journal-title":"PLoS. ONE"},{"issue":"January","key":"10.1016\/j.tice.2026.103747_bib36","article-title":"Protective effects of naringin on valproic acid-induced hepatotoxicity in rats","volume":"72","author":"Koroglu","year":"2021","journal-title":"Tissue Cell."},{"issue":"1","key":"10.1016\/j.tice.2026.103747_bib37","doi-asserted-by":"crossref","DOI":"10.1530\/JOE-22-0155","article-title":"Role of hepatic peroxisome proliferator-activated receptor \u03b3 in non-alcoholic fatty liver disease","volume":"257","author":"Lee","year":"2023","journal-title":"J. Endocrinol."},{"issue":"May","key":"10.1016\/j.tice.2026.103747_bib38","first-page":"1","article-title":"Dapagliflozin Alleviates Hepatic Steatosis by Restoring Autophagy via the AMPK-mTOR Pathway","volume":"12","author":"Li","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.tice.2026.103747_bib39","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s00204-018-2263-3","article-title":"Effects of antiepileptic drugs on lipogenic gene regulation and hyperlipidemia risk in Taiwan: a nationwide population-based cohort study and supporting in vitro studies","volume":"92","author":"Li","year":"2018","journal-title":"Arch. Toxicol."},{"issue":"6","key":"10.1016\/j.tice.2026.103747_bib40","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1111\/dom.15526","article-title":"A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin","volume":"26","author":"Lim","year":"2024","journal-title":"Diabetes Obes. & Metab."},{"key":"10.1016\/j.tice.2026.103747_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.cotox.2017.11.002","article-title":"NF-\u03baB in oxidative stress","volume":"7","author":"Lingappan","year":"2018","journal-title":"Curr. Opin. Toxicol."},{"issue":"6","key":"10.1016\/j.tice.2026.103747_bib42","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1053\/j.gastro.2020.01.027","article-title":"Identification of Lineage-Specific Transcription Factors That Prevent Activation of Hepatic Stellate Cells and Promote Fibrosis Resolution","volume":"158","author":"Liu","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.tice.2026.103747_bib43","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods (San. Diego Calif. )"},{"issue":"5","key":"10.1016\/j.tice.2026.103747_bib44","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/ana.20074","article-title":"Valproate Therapy and Nonalcoholic Fatty Liver Disease","volume":"55","author":"Luef","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tice.2026.103747_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.tox.2020.152585","article-title":"Involvement of CYP2E1-ROS-CD36\/DGAT2 axis in the pathogenesis of VPA-induced hepatic steatosis in vivo and in vitro","volume":"445","author":"Ma","year":"2020","journal-title":"Toxicology"},{"key":"10.1016\/j.tice.2026.103747_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1048728","article-title":"The serum acylcarnitines profile in epileptic children treated with valproic acid and the protective roles of peroxisome proliferator-activated receptor a activation in valproic acid-induced liver injury","volume":"13","author":"Ma","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.tice.2026.103747_bib47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S2468-1253(21)00261-2","article-title":"Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review","volume":"7","author":"Mantovani","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tice.2026.103747_bib48","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/549627","article-title":"Peroxisome proliferator-activated receptor targets for the treatment of metabolic diseases","volume":"2013","author":"Monsalve","year":"2013","journal-title":"Mediat. Inflamm."},{"issue":"5","key":"10.1016\/j.tice.2026.103747_bib49","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.jhep.2013.06.023","article-title":"Cell-specific PPAR\u03b3 deficiency establishes anti-inflammatory and anti-fibrogenic properties for this nuclear receptor in non-parenchymal liver cells","volume":"59","author":"Mor\u00e1n-Salvador","year":"2013","journal-title":"J. Hepatol."},{"issue":"8","key":"10.1016\/j.tice.2026.103747_bib50","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1096\/fj.10-173716","article-title":"Role for PPAR\u03b3 in obesity-induced hepatic steatosis as determined by hepatocyte-and macrophage-specific conditional knockouts","volume":"25","author":"Mor\u00e1n-Salvador","year":"2011","journal-title":"FASEB J."},{"issue":"2 February","key":"10.1016\/j.tice.2026.103747_bib51","first-page":"1","article-title":"Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model","volume":"17","author":"Morishita","year":"2022","journal-title":"PLoS. ONE"},{"issue":"1","key":"10.1016\/j.tice.2026.103747_bib52","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1210\/jc.2009-0473","article-title":"Sodium Glucose Cotransporter 2 Inhibitors as a New Treatment for Diabetes Mellitus","volume":"95","author":"Nair","year":"2010","journal-title":"J. Clin. Endocrinol. & Metab."},{"issue":"9","key":"10.1016\/j.tice.2026.103747_bib53","doi-asserted-by":"crossref","first-page":"G726","DOI":"10.1152\/ajpgi.00436.2015","article-title":"Liver-specific loss of Perilipin 2 alleviates diet-induced hepatic steatosis, inflammation, and fibrosis","volume":"310","author":"Najt","year":"2016","journal-title":"Am. J. Physiol. - Gastrointest. Liver Physiol."},{"issue":"3","key":"10.1016\/j.tice.2026.103747_bib54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1507\/endocrj.EJ12-0320","article-title":"Homeostasis model assessment of insulin resistance for evaluating insulin sensitivity in patients with type 2 diabetes on insulin therapy","volume":"60","author":"Okita","year":"2013","journal-title":"Endocr. J."},{"issue":"1","key":"10.1016\/j.tice.2026.103747_bib55","first-page":"1896","article-title":"The sodium\u2013glucose cotransporter 2 inhibitor ipragliflozin improves liver function and insulin resistance in Japanese patients with type 2 diabetes","volume":"12","author":"Okura","year":"2022","journal-title":"Sci. Rep. 2022 12"},{"issue":"1","key":"10.1016\/j.tice.2026.103747_bib56","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s11033-019-05134-6","article-title":"Melatonin ameliorates sodium valproate-induced hepatotoxicity in rats","volume":"47","author":"Oztopuz","year":"2020","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.tice.2026.103747_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/amsad\/202298","article-title":"Pioglitazone with SGLT2 inhibitors or GLP-1 receptor agonists in patients with type 2 diabetes and non-alcoholic fatty liver disease: could the combinations of an old friend with new players yield better outcomes?","volume":"10","author":"Papaetis","year":"2025","journal-title":"Arch. Med. Sci. Atheroscler. Dis."},{"key":"10.1016\/j.tice.2026.103747_bib58","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/538183","article-title":"Effects and Potential Mechanisms of Pioglitazone on Lipid Metabolism in Obese Diabetic KKAy Mice","volume":"2014","author":"Peng","year":"2014","journal-title":"PPAR Res."},{"issue":"11","key":"10.1016\/j.tice.2026.103747_bib59","article-title":"Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress","volume":"498","author":"Petito-da-Silva","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.tice.2026.103747_bib60","article-title":"Enavogliflozin, an SGLT2 Inhibitor, Improves Nonalcoholic Steatohepatitis Induced by High-Fat, High-Cholesterol Diet","author":"Pham","year":"2025","journal-title":"Diabetes & Metab. J."},{"issue":"10","key":"10.1016\/j.tice.2026.103747_bib61","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J. Gastroenterol. Hepatol. (Aust. )"},{"issue":"2","key":"10.1016\/j.tice.2026.103747_bib62","doi-asserted-by":"crossref","DOI":"10.1111\/jwas.13040","article-title":"Sustainable feed formulation to community-based aquaculture: Oreochromis niloticus fingerlings performance and antioxidant status","volume":"55","author":"Pires","year":"2024","journal-title":"J. World Aquac. Soc."},{"key":"10.1016\/j.tice.2026.103747_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.115237","article-title":"Pretreatment of hydroethanolic extract of Dillenia indica L. attenuates oleic acid induced NAFLD in HepG2 cells via modulating SIRT-1\/p-LKB-1\/AMPK, HMGCR & PPAR-\u03b1 signaling pathways","volume":"292","author":"Poornima","year":"2022","journal-title":"J. Ethnopharmacol."},{"key":"10.1016\/j.tice.2026.103747_bib64","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.934136","article-title":"Dapagliflozin protects against nonalcoholic steatohepatitis in db\/db mice","volume":"13","author":"Qiao","year":"2022","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.tice.2026.103747_bib65","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0059155","article-title":"Ginsenoside Rg1 Decreases A\u03b21\u201342 Level by Upregulating PPAR\u03b3 and IDE Expression in the Hippocampus of a Rat Model of Alzheimer\u2019s Disease","volume":"8","author":"Quan","year":"2013","journal-title":"PLOS ONE"},{"issue":"JUN","key":"10.1016\/j.tice.2026.103747_bib66","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3389\/fendo.2017.00147","article-title":"Does Valproic Acid Have Potential in the Treatment of Diabetes Mellitus?","volume":"8","author":"Rakitin","year":"2017","journal-title":"Front. Endocrinol."},{"issue":"7","key":"10.1016\/j.tice.2026.103747_bib67","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0103856","article-title":"Comparison of the Metabolic Syndrome Risk in Valproate-Treated Patients with Epilepsy and the General Population in Estonia","volume":"9","author":"Rakitin","year":"2014","journal-title":"PLOS ONE"},{"issue":"48","key":"10.1016\/j.tice.2026.103747_bib68","doi-asserted-by":"crossref","first-page":"68498","DOI":"10.1007\/s11356-021-15407-y","article-title":"Bioactive phytochemicals from Salvia officinalis attenuate cadmium-induced oxidative damage and genotoxicity in rats","volume":"28","author":"Rashwan","year":"2021","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"10.1016\/j.tice.2026.103747_bib69","doi-asserted-by":"crossref","DOI":"10.1155\/2010\/325183","article-title":"Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver","volume":"2010","author":"Rogue","year":"2010","journal-title":"PPAR Res."},{"issue":"2","key":"10.1016\/j.tice.2026.103747_bib70","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s10545-008-0841-x","article-title":"Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review","volume":"31","author":"Silva","year":"2008","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.tice.2026.103747_bib71","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-72967-8","article-title":"Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials","volume":"10","author":"Sinha","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.tice.2026.103747_bib72","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/bcpt.13190","article-title":"A role of peroxisome proliferator-activated receptor \u03b3 in non-alcoholic fatty liver disease","volume":"124","author":"Skat-R\u00f8rdam","year":"2019","journal-title":"Basic. & Clin. Pharmacol. & Toxicol."},{"issue":"5","key":"10.1016\/j.tice.2026.103747_bib73","first-page":"741","article-title":"Cross-talk between fatty acid and cholesterol metabolism mediated by liver X receptor-alpha","volume":"14","author":"Tobin","year":"2000","journal-title":"Mol. Endocrinol. (Baltim. Md. )"},{"key":"10.1016\/j.tice.2026.103747_bib74","unstructured":"Underwood, W., & Anthony, R. (2020). AVMA guidelines for the euthanasia of animals: 2020 edition. Retrieved on March, 2013(30), 2020-1."},{"issue":"2","key":"10.1016\/j.tice.2026.103747_bib75","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1528-1167.2009.02206.x","article-title":"The metabolic syndrome in overweight epileptic patients treated with valproic acid","volume":"51","author":"Verrotti","year":"2010","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.tice.2026.103747_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2022.100176","article-title":"The SGLT2 inhibitor dapagliflozin promotes systemic FFA mobilization, enhances hepatic \u03b2-oxidation, and induces ketosis","volume":"63","author":"Wallenius","year":"2022","journal-title":"J. Lipid Res."},{"issue":"8","key":"10.1016\/j.tice.2026.103747_bib77","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41574-018-0037-x","article-title":"Liver X receptors in lipid signalling and membrane homeostasis","volume":"14","author":"Wang","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"1","key":"10.1016\/j.tice.2026.103747_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12944-015-0172-5","article-title":"Schisandra polysaccharide inhibits hepatic lipid accumulation by downregulating expression of SREBPs in NAFLD mice","volume":"15","author":"Wang","year":"2016","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.tice.2026.103747_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2019.00819","article-title":"Lipidomic Profiling Reveals Disruption of Lipid Metabolism in Valproic Acid-Induced Hepatotoxicity","volume":"10","author":"Xu","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tice.2026.103747_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.768850","article-title":"Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence","volume":"12","author":"Yabiku","year":"2021","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.tice.2026.103747_bib81","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1147699","article-title":"Targeting macrophages in atherosclerosis using nanocarriers loaded with liver X receptor agonists: A narrow review","volume":"10","author":"Yang","year":"2023","journal-title":"Front. Mol. Biosci."},{"issue":"7","key":"10.1016\/j.tice.2026.103747_bib82","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1007\/s00125-004-1436-1","article-title":"Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty-acid-induced insulin resistance in the rat: comparison with metformin","volume":"47","author":"Ye","year":"2004","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.tice.2026.103747_bib83","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3748\/wjg.v10.i7.1047","article-title":"Effects of PPARg agonist pioglitazone on rat hepatic fibrosis","volume":"10","author":"Yuan","year":"2004","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"10.1016\/j.tice.2026.103747_bib84","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00210-015-1102-9","article-title":"Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure","volume":"388","author":"Zaitone","year":"2015","journal-title":"Naunyn-Schmiede \u2019S. Arch. Pharmacol. 2015 388"},{"issue":"7\u20138","key":"10.1016\/j.tice.2026.103747_bib85","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.bbadis.2010.04.002","article-title":"Muscle degeneration in neuraminidase 1-deficient mice results from infiltration of the muscle fibers by expanded connective tissue","volume":"1802","author":"Zanoteli","year":"2010","journal-title":"Biochim. Et. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.tice.2026.103747_bib86","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2007.11.037","article-title":"Hepatic Fatty Acid Transporter Cd36 Is a Common Target of LXR, PXR, and PPAR\u03b3 in Promoting Steatosis","volume":"134","author":"Zhou","year":"2008","journal-title":"Gastroenterology"}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816626004416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816626004416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T03:49:56Z","timestamp":1787456996000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816626004416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":86,"alternative-id":["S0040816626004416"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2026.103747","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin uncouples the anti-inflammatory and lipogenic effects of pioglitazone in valproic acid-induced steatohepatitis in rats: Lipid-sensing nuclear receptors (LXR\u03b1 and PPAR\u03b3) as the molecular nexus between hepatoprotection and lipogenesis","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2026.103747","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103747"}}